Claire Mazumdar Sells 2,631 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 2,631 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63. Following the completion of the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at approximately $6,356,812.16. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Trading Down 0.2%

Bicara Therapeutics stock opened at $18.47 on Friday. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.25 and a beta of -0.78. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $19.71. The stock’s 50 day moving average is $16.47 and its 200-day moving average is $15.78.

Analyst Upgrades and Downgrades

BCAX has been the topic of several recent research reports. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Wells Fargo & Company boosted their target price on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, Citigroup assumed coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They set an “outperform” rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $28.33.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Deutsche Bank AG grew its stake in shares of Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter. Mariner LLC boosted its holdings in shares of Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after acquiring an additional 1,902 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after acquiring an additional 1,962 shares in the last quarter.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.